208 related articles for article (PubMed ID: 16232378)
1. Cytokine targets in the treatment of myelodysplastic syndromes.
Verma A; List AF
Curr Hematol Rep; 2005 Nov; 4(6):429-35. PubMed ID: 16232378
[TBL] [Abstract][Full Text] [Related]
2. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.
Katsoulidis E; Li Y; Yoon P; Sassano A; Altman J; Kannan-Thulasiraman P; Balasubramanian L; Parmar S; Varga J; Tallman MS; Verma A; Platanias LC
Cancer Res; 2005 Oct; 65(19):9029-37. PubMed ID: 16204077
[TBL] [Abstract][Full Text] [Related]
3. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
List AF
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
[TBL] [Abstract][Full Text] [Related]
4. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes.
Allampallam K; Shetty V; Hussaini S; Mazzoran L; Zorat F; Huang R; Raza A
Anticancer Res; 1999; 19(6B):5323-8. PubMed ID: 10697556
[TBL] [Abstract][Full Text] [Related]
5. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.
Keith T; Araki Y; Ohyagi M; Hasegawa M; Yamamoto K; Kurata M; Nakagawa Y; Suzuki K; Kitagawa M
Br J Haematol; 2007 May; 137(3):206-15. PubMed ID: 17408459
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic growth factors in myelodysplastic syndromes.
Blinder VS; Roboz GJ
Curr Hematol Rep; 2003 Nov; 2(6):453-8. PubMed ID: 14561388
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation in myelodysplastic syndromes.
Sekeres MA; List A
Best Pract Res Clin Haematol; 2006; 19(4):757-67. PubMed ID: 16997181
[TBL] [Abstract][Full Text] [Related]
8. Supportive care, growth factors, and new therapies in myelodysplastic syndromes.
Hellström-Lindberg E; Malcovati L
Blood Rev; 2008 Mar; 22(2):75-91. PubMed ID: 18068281
[TBL] [Abstract][Full Text] [Related]
9. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
Hellström-Lindberg E; Malcovati L
Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.
Musto P
Leuk Res; 2004 Apr; 28(4):325-32. PubMed ID: 15109529
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
12. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.
Aguayo A
Curr Hematol Rep; 2004 May; 3(3):184-91. PubMed ID: 15087066
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
Bowen DT
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
[TBL] [Abstract][Full Text] [Related]
14. Cytokines and signal transduction.
Hideshima T; Podar K; Chauhan D; Anderson KC
Best Pract Res Clin Haematol; 2005; 18(4):509-24. PubMed ID: 16026734
[TBL] [Abstract][Full Text] [Related]
15. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells.
Deeg HJ; Jiang PY; Holmberg LA; Scott B; Petersdorf EW; Appelbaum FR
Leuk Res; 2004 Nov; 28(11):1177-80. PubMed ID: 15380342
[TBL] [Abstract][Full Text] [Related]
16. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
Cazzola M
Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
[TBL] [Abstract][Full Text] [Related]
17. Modulation of angiogenesis in patients with myelodysplastic syndrome.
Estey EH
Best Pract Res Clin Haematol; 2004 Dec; 17(4):623-39. PubMed ID: 15494299
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological differentiation and anti-apoptotic therapy in myelodysplastic syndromes.
List AF
Forum (Genova); 1999; 9(1):35-45. PubMed ID: 10101209
[TBL] [Abstract][Full Text] [Related]
19. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K
Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.
Navas T; Zhou L; Estes M; Haghnazari E; Nguyen AN; Mo Y; Pahanish P; Mohindru M; Cao T; Higgins LS; Platanias LC; List A; Verma A; Bhagat T; Gajavelli S; Kambhampati S
Leuk Lymphoma; 2008 Oct; 49(10):1963-75. PubMed ID: 18949619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
